Pharmbiotest Poland Joins Industry Leaders at BIOEQ25 in Amsterdam

Our team had the incredible opportunity to attend the 3rd Bioequivalence Conference 2025 (BIOEQ25), organized in partnership with Medicines for Europe. The event gathered industry leaders, regulatory experts, and scientists to discuss the latest advancements in bioequivalence, international harmonization, and regulatory alignment.

📌 Key highlights from the conference:

• Updates on ICH M13 – next steps for implementation and key considerations for M13C.
• The growing role of Model-Informed Drug Development (MIDD) and insights into ICH M15.
• Critical discussions on compliance in bioequivalence studies and the evolution of Good Clinical Practice (ICH E6).
• A strong focus on global regulatory convergence, paving the way for streamlined development and faster patient access to high-quality medicines.

As a CRO specializing in bioequivalence studies, clinical trials, and generic drug development, we value such platforms that foster collaboration and innovation in regulatory science. It was a pleasure to connect with industry experts and explore new ways to enhance patient access to safe and effective medicines.

👏 A big thank you to the organizers and speakers for making BIOEQ25 such a valuable experience!